Eli Lilly to release data on weight loss drug retatrutide in 2025

Eli Lilly on Thursday said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, a few months earlier than anticipated. 

The company expects to provide results from a 68-week study in people with obesity and osteoarthritis of the knee in 2025, according to fourth-quarter earnings slides on its website. Eli Lilly previously said that phase three study was expected to finish in February 2026. 

It is among at least nine closely watched clinical trials on retatrutide, which works differently from the obesity and diabetes treatments on the market and appears to be even more effective at weight loss. 

“We believe this potential new medicine can deliver even more weight loss than tirzepatide and it could potentially…